| pubmed-article:9681417 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9681417 | lifeskim:mentions | umls-concept:C1155065 | lld:lifeskim |
| pubmed-article:9681417 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:9681417 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:9681417 | pubmed:dateCreated | 1998-9-21 | lld:pubmed |
| pubmed-article:9681417 | pubmed:abstractText | Important considerations for T lymphocyte-based gene therapy include efficient gene delivery and expression in primary, human T cells. In this study, retrovirus-mediated gene transfer and the fate of proviral gene expression were evaluated in human T cells activated using (1) immobilized anti-CD3 monoclonal antibody (MAb) plus interleukin 2, or (2) cis costimulation using beads carrying coimmobilized anti-CD3 and anti-CD28 MAbs. By cross-linking the CD3 and CD28 receptors, these MAbs mimic in vivo signaling events, leading to cytokine production and proliferation. A modified human interleukin 1beta (IL-1beta) cDNA inserted into the MFG retroviral vector served as an indicator gene. Retroviral transduction frequencies were similar for T lymphocytes activated by the respective methods. However, early after MAb stimulation and virus exposure, proviral gene expression was greater at the RNA and protein levels in optimized anti-CD3/anti-CD28 bead-activated T cells, corresponding with augmented endogenous cytokine responses and mitogenesis. Proviral gene expression was not regulated by extrinsic cell factors present in activated T cell supernatants. Regardless of the MAb stimulation method, proviral IL-1beta expression declined in later T cell cultures concomitant with a decrease in cellular cytokines. Restimulation by either method reinduced both T cell activity and vector expression. Our finding that proviral gene regulation is downmodulated in the absence of T cell signaling events has implications for clinical strategies using retrovirus-modified T cells. | lld:pubmed |
| pubmed-article:9681417 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9681417 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9681417 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9681417 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9681417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9681417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9681417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9681417 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9681417 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9681417 | pubmed:issn | 1043-0342 | lld:pubmed |
| pubmed-article:9681417 | pubmed:author | pubmed-author:VYTT | lld:pubmed |
| pubmed-article:9681417 | pubmed:author | pubmed-author:TrevorK TKT | lld:pubmed |
| pubmed-article:9681417 | pubmed:author | pubmed-author:QuinnE RER | lld:pubmed |
| pubmed-article:9681417 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9681417 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9681417 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9681417 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9681417 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9681417 | pubmed:pagination | 1457-67 | lld:pubmed |
| pubmed-article:9681417 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:meshHeading | pubmed-meshheading:9681417-... | lld:pubmed |
| pubmed-article:9681417 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9681417 | pubmed:articleTitle | T cell activation modulates retrovirus-mediated gene expression. | lld:pubmed |
| pubmed-article:9681417 | pubmed:affiliation | Vince Lombardi Gene Therapy Laboratory, Immunotherapy, Research and Treatment Institute, St. Luke's Medical Center, Milwaukee, WI 53201, USA. | lld:pubmed |
| pubmed-article:9681417 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9681417 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9681417 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9681417 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9681417 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9681417 | lld:pubmed |
